Product/Composition:- | Cefalexin (1st Gen) Capsules and tablets |
---|---|
Strength:- | 250 mg, 500 mg |
Form:- | Oral Capsules and Tablets |
Reference Brands:- | Keflex(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Cephalexin inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins, leading to bacterial lysis. It is effective against skin, respiratory, and urinary tract infections. Benefits include broad-spectrum activity, rapid bacterial eradication, safety, and oral convenience, making it a reliable choice for outpatient treatment of common bacterial infections.
Cephalexin oral capsules and tablets are approved across the EU and US for treating bacterial infections such as skin, respiratory, and urinary tract infections. In the EU, brands like Keflex and generic formulations are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval is based on extensive clinical data, with generic options readily available. Both regions require detailed dossiers including clinical trial results, quality control, and pharmacovigilance plans for initial approval and safety monitoring. For expert support with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access, ensuring adherence to European and US standards for safe, effective use.